DXCM实时信号 | 通过Getagraph.com最大化利润

购买 5292 min ago

@ $137.94

发出时间: 26 Apr 2024 @ 03:42

回报率: -9.86%

上一信号: Apr 26 - 00:41

上一信号: 出售

回报率: 0.81 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally...

Stats
今日成交量	8.58M
平均成交量	3.18M
市值	49.24B
EPS	$0 ( 2024-04-25 )
下一个收益日期	( $0.390 ) 2024-07-25
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	80.74
ATR14	$13.59 (10.93%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	Dolan Matthew Vincent	Sell	1 990	Common Stock
2024-04-08	Sayer Kevin R	Sell	27 272	Common Stock
2024-04-08	Sayer Kevin R	Sell	22 361	Common Stock
2024-03-28	Brown Michael Jon	Sell	2 524	Common Stock
2024-03-28	Brown Michael Jon	Sell	100	Common Stock

INSIDER POWER
-3.99
Last 99 transactions
Buy: 330 077 \| Sell: 354 468

音量相关性

長: -0.86 (strong negative)

短: -0.83 (strong negative)

Signal:(37) Neutral

DexCom Inc 相关性

10 最正相关
SVBI	0.821
BOSC	0.807

10 最负相关
QTEK	-0.802

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

DexCom Inc 相关性 - 货币/商品

-0.32
( neutral )

-0.84
( strong negative )

0.00
( neutral )

-0.61
( weak negative )

0.55
( weak )

0.26
( neutral )

DexCom Inc 财务报表

Annual	2023
营收:	$3.62B
毛利润:	$2.29B (63.19 %)
EPS:	$1.400

FY	2023
营收:	$3.62B
毛利润:	$2.29B (63.19 %)
EPS:	$1.400

FY	2022
营收:	$2.91B
毛利润:	$1.88B (64.72 %)
EPS:	$0.880

FY	2021
营收:	$2.45B
毛利润:	$1.68B (68.63 %)
EPS:	$0.400

Financial Reports:

No articles found.

DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.